UK markets closed

OncoCyte Corporation (0KCC.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.9685-0.0265 (-0.88%)
At close: 02:52PM GMT
Full screen
Previous close2.9950
Open2.9685
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range2.9685 - 2.9685
52-week range0.2082 - 4.2256
Volume17
Avg. volume368
Market cap2.703M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)-0.7710
Earnings date01 Apr 2024 - 05 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

    IRVINE, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that CEO Josh Riggs will be presenting a corporate overview at the upcoming Sequire Investor Summit 2024. The conference is scheduled for January 23-25, 2024 at the Condado Vanderbilt Hotel in San Juan, Puerto Rico. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico

  • GlobeNewswire

    Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

    - Significant unmet need for regulated product in $2B US testing market - Opportunity for expedited pathway for kitted product in development IRVINE, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced it has begun the FDA single-site process for its VitaGraft transplant assays. The single-site process is a well-established pathway for Lab Developed Tests (LDTs) to seek regulatory approval. This move positions Oncocyte wi

  • GlobeNewswire

    Oncocyte Reports Third Quarter 2023 Financial Results

    -Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023 at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial re